NCT06207032 TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
| NCT ID | NCT06207032 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tempus AI |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-06-26 |
| Primary Completion | 2029-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-06-26 with a primary completion date of 2029-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years of age 2. Willing to participate in the research 3. Able to provide informed consent 4. Must be diagnosed with cancer Exclusion Criteria: 1\. Not willing or able to have additional blood samples collected
Contact & Investigator
Michelle Ting-Lin, MD
STUDY DIRECTOR
Tempus AI, Inc.
Frequently Asked Questions
Who can join the NCT06207032 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06207032 currently recruiting?
Yes, NCT06207032 is actively recruiting participants. Contact the research team at aries@tempus.com for enrollment information.
Where is the NCT06207032 trial being conducted?
This trial is being conducted at Birmingham, United States, Whittier, United States, Norwich, United States, Jacksonville, United States and 11 additional locations.
Who is sponsoring the NCT06207032 clinical trial?
NCT06207032 is sponsored by Tempus AI. The principal investigator is Michelle Ting-Lin, MD at Tempus AI, Inc.. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.